Recent Finacing
Recent Raise
CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an oral brain-penetrant p38α inhibitor, to treat synaptic dysfunction in age-related neurologic disorders, currently in Phase 2b for DLB.
Focus Areas
Total Raised
Funding round
See the team members at CervoMed.
